The briefing
A phase 1, first-in-human study is evaluating the safety and tolerability of a microneedle stamp that delivers peanut protein through the skin. Researchers aim to assess whether the approach can be administered safely as a potential pathway to desensitization.
Original headline
First-in-human trial tests microneedle stamp approach for peanut allergy